Safety of GVHD prophylaxis in Haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide in combination with thymoglobuli
Phase 1
Recruiting
- Conditions
- Hematopoietic malignancy
- Registration Number
- JPRN-UMIN000014472
- Lead Sponsor
- Department of Oncology and Hematology, Oita University Faculity of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
Cases with a sufficient amount (2.0x106/kg CD34-positive cells) could not be harvested peripheral blood hematopoietic stem cells from donor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Engraftment and survival without grade III-IV acute GVHD at day60
- Secondary Outcome Measures
Name Time Method 1.1 year progression-free survival and overall survival 2.1 year non relapse mortarity 3.primary graft failure 4.secondary graft failure 5.acute and chronic GVHD